Metabolic syndrome and lower urinary tract symptoms: The role of inflammation

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 1, 2013, Pages 100-105

  Gacci, M ^a   Vignozzi, L ^a   Sebastianelli, A ^a   Salvi, M ^a   Giannessi, C ^a   De Nunzio, C ^b   Tubaro, A ^b   Corona, G ^c   Rastrelli, G ^c   Santi, R ^a   Nesi, G ^a   Serni, S ^a   Carini, M ^a   Maggi, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c BELLARIA HOSPITAL   (Italy)

Author keywords

BPH; lower urinary tract symptoms; LUTS; metabolic syndrome; MetS; prostate

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; INFLAMMATION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; PROSTATECTOMY; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION; TRIACYLGLYCEROL BLOOD LEVEL; UROFLOWMETRY; PATHOLOGY;

AGED; HUMANS; INFLAMMATION; LOWER URINARY TRACT SYMPTOMS; MALE; METABOLIC SYNDROME X; PROSTATECTOMY; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES;

EID: 84873726699     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.44     Document Type: Article

References (35)

1. Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809-825.
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. Standardisation sub-committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation subcommittee of the International Continence Society. Urology 2003; 61: 37-49. (Pubitemid 36151708)
3. Samdeep M, Kevin T. McVary Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 2010; 20: 7-12.
4. Roherborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res 2008; 20(Suppl 3): S11-S18.
5. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157-162. (Pubitemid 128545860)
6. Hammarsten J, Högstedt B. Calculated fast-growing benign prostatic hyperplasia-a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 2002; 36: 330-338. (Pubitemid 35373619)
7. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipi-daemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006; 370: 89-93. (Pubitemid 44080171)
8. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599-604. (Pubitemid 34793304)
9. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199-203.
10. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61: 560-570.
11. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011; 60: 106-117.
12. Gacci M, Bartoletti R, Figlioli S, Sarti E, Eisner B, Boddi V et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int 2003; 91: 196-200. (Pubitemid 36232834)
13. Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol 2001; 166: 172-176. (Pubitemid 32565372)
14. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
15. Corona G, Mannucci E, Petrone L, Schulman C, Balercia G, Fisher AD et al. A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction. J Sex Med 2007; 4: 789-796. (Pubitemid 46779316)
16. Curtis Nickel J. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 2008; 35: 109-115.
17. Smith AD, Badlani G, Preminger GM, Kavoussi LR. Smith's Textbook of Endourology. 3rd edn, 2011.
18. Aarnink RG, de la Rosette JJ, Huynen AL, Giesen RJ, Debruyne FM, Wijkstra H. Standardized assessmet to enhance the diagnostic value of prostate volume; part i: morphometry in patients with lower urinary tract symptoms. Prostate 29: 317-326 1996. (Pubitemid 26372605)
19. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405. (Pubitemid 26317480)
20. Rove KO, Sullivan KF, Crawford ED. High-intensity focused ultrasound: ready for primetime. Urol Clin North Am 2010; 37: 27-35.
21. Hammarsten J, Hogstedt B. Hyperinsulinemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151-158. (Pubitemid 32171181)
22. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 2562-2568. (Pubitemid 44024618)
23. Lee RK, Chung D, Chughtai B, Te AE, Kaplan SA. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int 2012; 110: 540-545.
24. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 33: 475-488.
25. Schauer IG, Rowley DR. The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation 2011; 82: 200-210.
26. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379-1384.
27. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol 2005; 7(Suppl 9): S3-S14.
28. Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol 2012; 212: 71-84.
29. Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L et al. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol 2012; 132: 80-92.
30. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009; 6: 3274-3288.
31. Vignozzi L, Morelli A, Filippi S, Comeglio P, Chavalmane AK, Marchetta M et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med 2011; 8: 57-77.
32. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185: 1793-1803.
33. Crawford ED, Wilsson SS, Roehroborn CG. MTOPS study group, Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006; 175: 1422-1426.
34. Yang XJ, Lecksell K, Short K, Gottesman J, Peterson L, Bannow J et al. Does longterm finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 53: 696-700. (Pubitemid 29163032)
35. Nickel JC, Downey J, Pontari MA, Shoskes DA, Zeitlin SI. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int 2004; 93: 991-995. (Pubitemid 38758620)